Harmony Biosciences Holdings (HRMY) Amortization of Deferred Charges (2019 - 2023)

Harmony Biosciences Holdings (HRMY) has 5 years of Amortization of Deferred Charges data on file, last reported at $424000.0 in Q2 2023.

• For the quarter ending Q2 2023, Amortization of Deferred Charges rose 3.16% year-over-year to $424000.0; the trailing twelve-month figure through Jun 2023 stood at $1.7 million (down 1.18% YoY), and the FY2022 full-year result was $1.7 million, down 25.69% from the prior year.
• Amortization of Deferred Charges climbed to $424000.0 in Q2 2023, from $416000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q4 2020 to a low of $185000.0 in Q3 2019.
• A 5-year average of $471750.0 and a median of $417000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges soared 562.86% in 2020 and sank 69.97% in 2021, its largest moves.
• Tracing HRMY's Amortization of Deferred Charges over 5 years: stood at $210000.0 in 2019, then soared by 562.86% to $1.4 million in 2020, then slumped by 69.97% to $418000.0 in 2021, then climbed by 0.96% to $422000.0 in 2022, then climbed by 0.47% to $424000.0 in 2023.
• Business Quant data shows HRMY's Amortization of Deferred Charges at $424000.0 in Q2 2023, $416000.0 in Q1 2023, and $422000.0 in Q4 2022.